During the last session, Acelyrin Inc (NASDAQ:SLRN)’s traded shares were 0.69 million, with the beta value of the company hitting 1.09. The 52-week high for the SLRN share is $7.25, that puts it down -229.55 from that peak though still a striking 15.91% gain since the share price plummeted to a 52-week low of $1.85. The company’s market capitalization is $222.00M, and the average intraday trading volume over the past 10 days was 0.99 million shares, and the average trade volume was 1.95 million shares over the past three months.
Acelyrin Inc (SLRN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SLRN has a Sell rating from 0 analyst(s) out of 14 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.95.
Acelyrin Inc (NASDAQ:SLRN) trade information
The stock’s 5-day price performance is 2.33%, and it has moved by -21.15% in 30 days. Based on these gigs, the overall price performance for the year is -57.20%. The short interest in Acelyrin Inc (NASDAQ:SLRN) is 3.65 million shares and it means that shorts have 3.22 day(s) to cover.
The consensus price target of analysts on Wall Street is $10.5, which implies an increase of 79.05% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $15 respectively. As a result, SLRN is trading at a discount of -581.82% off the target high and -172.73% off the low.
SLRN Dividends
Acelyrin Inc is due to release its next quarterly earnings on 2025-Mar-18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Acelyrin Inc (NASDAQ:SLRN)’s Major holders
Acelyrin Inc insiders own 8.06% of total outstanding shares while institutional holders control 105.48%, with the float percentage being 114.72%. AYURMAYA CAPITAL MANAGEMENT COMPANY, LP is the largest shareholder of the company, while 177.0 institutions own stock in it. As of 2024-06-30, the company held over 9.33 million shares (or 9.4136% of all shares), a total value of $41.17 million in shares.
The next largest institutional holding, with 7.41 million shares, is of CITADEL ADVISORS LLC’s that is approximately 7.4732% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $32.68 million.
Also, the Mutual Funds coming in first place with the largest holdings of Acelyrin Inc (SLRN) shares are T. Rowe Price Small-Cap Stock Fund, Inc. and T. Rowe Price Small-Cap Value Fund, Inc. . Data provided on Dec 31, 2024 indicates that T. Rowe Price Small-Cap Stock Fund, Inc. owns about 3.63 shares. This amounts to just over 3.59 percent of the company’s overall shares, with a $7.98 million market value. The same data shows that the other fund manager holds slightly less at 2.84, or about 2.81% of the stock, which is worth about $6.24 million.
